'Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Cancer

An ‘innovative’ study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved ‘unprecedented’ pathologic responses, with no recurrences.
Medscape Medical News